EBS Emergent Biosolutions Inc.

+0.56  (+1%)
Previous Close 43.09
Open 43.27
Price To Book 2.28
Market Cap 2,252,340,000
Shares 51,600,000
Volume 267,880
Short Ratio 13.49
Av. Daily Volume 349,139

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 9, 2017. Completion due 2019.
Influenza A
Approved May 17, 2012.
Anthrax Vaccine
Approved November 24, 2015.
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Phase 2b data likely due 2019.
End-stage renal disease
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
Zika vaccine
Phase 3 trial planned for 2019.
Anthrax vaccine
Phase 2 interim analysis April 16, 2019.
Chikungunya virus

Latest News

  1. Emergent BioSolutions to Participate in Series of Investor Conferences
  2. Here's Why Emergent BioSolutions (NYSE:EBS) Has A Meaningful Debt Burden
  3. Emergent BioSolutions Looks to the Second Half for Growth
  4. Emergent BioSolutions Inc (EBS) Q2 2019 Earnings Call Transcript
  5. Edited Transcript of EBS earnings conference call or presentation 1-Aug-19 9:00pm GMT
  6. Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates
  7. Emergent Biosolutions (EBS) Q2 Earnings Lag Estimates
  8. Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
  9. Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
  10. Earnings Preview: Emergent Biosolutions (EBS) Q2 Earnings Expected to Decline
  11. Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
  12. Here's What Emergent BioSolutions Inc.'s (NYSE:EBS) P/E Is Telling Us
  13. Here’s What Hedge Funds Think About Emergent Biosolutions Inc (EBS)
  14. See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
  15. Before You Buy Emergent BioSolutions Inc. (NYSE:EBS), Consider Its Volatility
  16. Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic
  17. Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)
  18. Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine